Abstract

The present disclosure relates to methods for treating infectious disorders. In particular, the disclosure provides BTN3A activating antibodies, and their use in treating infectious disorders in a human subject in need thereof, such as disorders caused by SARS-Cov2 or Coxiella burnetii infection.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 31/04 - Antibacterial agents
• A61P 31/14 - Antivirals for RNA viruses

Abstract

1lim*lim*

IPC Classes  ?

• G01T 1/29 - Measurement performed on radiation beams, e.g. position or section of the beamMeasurement of spatial distribution of radiation

Abstract

The present invention relates to the field of medicine. It more particularly relates to new anti-soluble CD146 (sCD146) protein antibodies, in particular multispecific antibodies comprising antigen binding regions that specifically bind sCD146 and VEGF proteins, to nucleic acids and vectors encoding and/or expressing such antibodies, and to cells and compositions comprising such product(s), as well as to uses thereof, typically in the treatment of cancer, preferably cancer resistant to treatments involving an anti-VEGF antibody. The invention also relates to uses of anti-sCD146 antibodies for predicting or monitoring the response of a subject to a treatment of cancer involving an anti-VEGF agent, and to related methods.

IPC Classes  ?

• C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• A61P 35/00 - Antineoplastic agents

Abstract

A vascular prosthesis may be implanted in a vessel, having substantially a T-shape, that includes a proximal tubular part forming the base of the “T” and a distal tubular part forming the head of the “T”. The second end portion of the distal tubular part is formed by a flap. The flap is opposed to a circumferential indentation in the deployed position. The structural frame of the flap includes an arched segment connected at its ends to the intermediate portion of the distal tubular part. The arched segment is bendable so as to form a joint for the folding/unfolding movement of the flap.

IPC Classes  ?

• A61F 2/06 - Blood vessels
• A61F 2/07 - Stent-grafts

Abstract

A percutaneous bypass method for implanting a bypass graft between two vessels is described. The bypass graft comprises a first part and a second part, each having a tubular shape and comprising respective lumens. The method comprises the step of inserting a second sheath, from the outside to the inside of a bypass portion of the first part, through a puncture therein, and retracting the second sheath so as to deploy and implant a hook portion of the second part into the second vessel, and deploy a bypass portion of the second part outside the second vessel, from the second vessel to the first part, and within the lumen of the first part.

IPC Classes  ?

• A61F 2/07 - Stent-grafts
• A61F 2/962 - Instruments specially adapted for placement or removal of stents or stent-grafts having an outer sleeve
• A61F 2/06 - Blood vessels

Abstract

The present invention relates to a dry foam comprising agar-agar characterized by an elasticity modulus from 0.02 to 0.6 MPa, particularly from 0.15 to 0.6 MPa, more particularly from 0.3 to 0.4 MPa, a manufacturing process thereof and the uses thereof in particular as an embolization agent.

IPC Classes  ?

• A61L 24/00 - Surgical adhesives or cementsAdhesives for colostomy devices
• A61L 24/08 - Polysaccharides
• C08J 9/28 - Working-up of macromolecular substances to porous or cellular articles or materialsAfter-treatment thereof by elimination of a liquid phase from a macromolecular composition or article, e.g. drying of coagulum

Abstract

A computer implemented method and a system of encryption of genomic data of a biological sample are provided, that improve the security of genetic information obtained from a sample, while guaranteeing traceability and identity-vigilance throughout the analysis chain. The computer implemented method and system disclosed herein allows a high level of identity-vigilance, improved labelling and traceability and provide a high level of confidentiality of genomics data.

IPC Classes  ?

• G16B 50/40 - Encryption of genetic data
• H04L 9/08 - Key distribution

Abstract

The invention relates to the field of imaging, diagnostic, internal vectorized radiotherapy and nuclear medicine. Inventors herein describe new products for use for labelling, detecting and/or imaging angiogenesis, vasculogenesis or a tissue or organ expressing the APJ receptor; for use for detecting, measuring, diagnosing, staging and/or monitoring angiogenesis, vasculogenesis, an angiogenesis- and/or vasculogenesis-related disease or disorder, and/or a disease or disorder inducing or modulating the expression of a APJ receptor in a tissue or organ; for use for preventing or treating angiogenesis, vasculogenesis, an angiogenesis- and/or vasculogenesis-related disease or disorder, and/or a disease or disorder inducing or modulating the expression of a APJ receptor in a tissue or organ; or for use for evaluating or monitoring the therapeutic effect of an angiogenic or antiangiogenic treatment or of an APJ receptor-targeted treatment. Compositions and kits comprising such products are also herein described as well as uses thereof.

IPC Classes  ?

• A61K 51/08 - Peptides, e.g. proteins
• A61K 49/00 - Preparations for testing in vivo
• A61P 35/00 - Antineoplastic agents

Abstract

Coronaviridae is a family of enveloped, positive-sense, single-stranded RNA viruses. The emergence of a new beta-coronavirus SARS-CoV-2 has led to a major health-related crisis associated with a significant mortality in intensive care units, due to the pulmonary complications of COVID-19. The inventors showed that BAY-2402234 is suitable for inhibiting replication of coronavirus and thus would be suitable for the treatment of infections mediated by said type of virus.

IPC Classes  ?

• A61K 31/4196 - 1,2,4-Triazoles
• A61K 38/21 - Interferons
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
• A61K 31/4706 - 4-Aminoquinolines8-Aminoquinolines, e.g. chloroquine, primaquine

Abstract

Coronaviridae is a family of enveloped, positive-sense, single-stranded RNA viruses. The emergence of a new betacoronavirus SARS-CoV-2 has led to a major health-related crisis associated with a significant mortality in intensive care units, due to the pulmonary complications of COVID-19. The inventors showed that Vidofludimus is suitable for inhibiting replication of coronavirus and thus would be suitable for the treatment of infections mediated by said type of virus.

IPC Classes  ?

• A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
• A61P 31/14 - Antivirals for RNA viruses
• A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine

Abstract

The present disclosure relates to methods for treating infectious disorders. In particular, the disclosure provides BTN3A activating antibodies, and their use in treating infectious disorders in a human subject in need thereof, such as disorders caused by SARS-Cov2 or Coxiella burnetii infection.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 31/04 - Antibacterial agents
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present disclosure relates to methods for treating infectious disorders. In particular, the disclosure provides BTN3A activating antibodies, and their use in treating infectious disorders in a human subject in need thereof, such as disorders caused by SARS-Cov2 or Coxiella burnetii infection.

IPC Classes  ?

• A61P 31/04 - Antibacterial agents
• A61P 31/14 - Antivirals for RNA viruses
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The present invention relates to an apheresis column loaded with a solid support comprising a composition comprising at least one peptide selected from the group consisting of: —the αI7I-I85cit peptide of amino acid sequence VDIDIKIX1SCX2GSCS (SEQ ID NO: 8) wherein X1 and X2 each represent a citmllyl residue, —the α62I-635Cit peptide of amino acid sequence X1GHAKSX2PVX3GIHTS (SEQ ID NO: 12) wherein X1, X2 and X3 each represent a citmllyl residue—the P60-74cit-NH2 peptide of amino acid sequence X1PAPPPISGGGYX2AX3 (SEQ ID NO: 15) wherein X1 and X2 each represent a citmllyl residue and X3 represents a citmllyl derivative with a carboxamide group and—the peptide, referred to as the Ac-a36-50crt peptide, having the amino acid sequence GPX1VVEX2HQSACKDS (SEQ ID NO: 6) wherein the residue G at the N-terminal is acetylated and wherein X1 and X2 each represent a citmllyl residue and/or the a36-50cit peptide of amino acid sequence GPX1VVEX2HQSACKDS (SEQ ID NO: 5) wherein X1 and X2 each represent a citmllyl residue.

IPC Classes  ?

• A61M 1/34 - Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration, diafiltration
• A61M 1/36 - Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation

Abstract

A vascular prosthesis configured to be implanted in a vessel, having substantially a T-shape, comprises a proximal tubular part forming the base of the “T” and a distal tubular part forming the head of the “T”. The proximal tubular part has a first lumen, the distal tubular part has a second lumen, and the first and second lumens are fluidly connected to form a common lumen. The distal tubular part comprises a first end portion, a second end portion, and an intermediate portion extending axially between the first and second end portions. The first and second end portions are radially expandable. The proximal tubular part is connected to the intermediate portion and the second end portion is movable between a retracted position in which the second end portion is axially restrained and a deployed position in which the second end portion is axially deployed.

IPC Classes  ?

• A61F 2/06 - Blood vessels
• A61F 2/07 - Stent-grafts

Abstract

The invention is related to a method for measuring the variability of the red blood cells deformability of an individual by determining the amount of red blood cells having a tank-treading motion in a population of red blood cells from a tested blood sample of said individual, and comparing the amount to a reference amount. The determination of the amount of red blood cells having a tank-treading motion is carried out using a visualisation means such as a brightfield microscope.

IPC Classes  ?

• G01N 33/49 - Physical analysis of biological material of liquid biological material blood
• G01N 15/14 - Optical investigation techniques, e.g. flow cytometry
• G06T 7/246 - Analysis of motion using feature-based methods, e.g. the tracking of corners or segments
• G06T 7/00 - Image analysis
• G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

A vascular prosthesis (1) configured to be implanted in a vessel, having substantially a T-shape, comprises a proximal tubular part (10) forming the base of the "T" and a distal tubular part (20) forming the head of the "T". The second end portion (220) of the distal tubular part (20) is formed by a flap (222). The flap (222) is opposed to a circumferential indentation (223) in the deployed position. The structural frame (224) of the flap (222) comprises an arched segment (227) connected at its ends to the intermediate portion (230) of the distal tubular part (20). The arched segment (227) is bendable so as to form a joint for the folding/unfolding movement of the flap (222).

IPC Classes  ?

• A61F 2/07 - Stent-grafts
• A61F 2/856 - Single tubular stent with side portal passage
• A61F 2/06 - Blood vessels

Abstract

As advanced cancer has poor prognosis, its detection and treatment at the earliest stages is critical to increase cancer survival rate. Therefore, elucidating the determinants of the intra-lesion immune reaction during cancer's developments is critical for moving into precision medicine and immunotherapy-based cancer prevention. Adaptive immune response within tumors was shown to be the strongest at the earliest stage of carcinoma. Thus, the inventors hypothesized that the immune microenvironment and adaptive immunity were first established at early stage of lung carcinogenesis. Here they identified changes in the tumor molecular profile and its microenvironment during the successive steps of lung squamous carcinogenesis, using gene expression profiling and multispectral imaging. A unique and invaluable dataset of (9) morphological stages of development was analyzed, including (122) well-annotated biopsies from (77) patients. In particular, the inventors show that immune activation and immune escape occur before tumor invasion, and that immunosuppressive cytokines and checkpoint receptors immune escape mechanisms are concomitant with anti-tumor immunity in high-grade dysplasia. Thus, the present invention relates to methods of predicting and preventing cancer in subjects having premalignant lesions.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to field of treatment of rheumatoid arthritis. The inventors propose that PAD4, one of the enzymes which convert arginine into citrulline, is a target antigen for T cells that help the production of ACPA. They recently demonstrated that PAD immunization triggers anti-citrullinated fibrinogen antibody production in normal mice. Here, they demonstrate that the risk (OR) to develop RA associated with each of 12 HLA-DRB1 genotype correlates with the likelihood for the two HLA-DR molecules encoded by each genotype to bind at least one random peptide from PAD4, but not from citrullinated or native fibrinogen. PBLs from patients with RA, PsA and controls proliferate to PAD4 and they identify, notably, a peptide from PAD4, p8 (SEQ ID NO: 6), that stimulates T cells from RA patients and a few patients with PsA. Proliferative responses to p8 are associated with RA, shared epitope positive HLA-DR alleles and antibodies to PAD4. Thus the present invention relates to a peptide derived from the PAD4 protein and its use in the treatment and prevention of rheumatoid arthritis.

IPC Classes  ?

• C12N 9/78 - Hydrolases (3.) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61K 38/50 - Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase

Abstract

A percutaneous bypass method for implanting a bypass graft (1) between two vessels (2, 3) 5 is described. The bypass graft (1) comprises a first part (20) and a second part (30), each having a tubular shape and comprising respective lumens. The method comprises the step of inserting a second sheath (3000), from the outside to the inside of a bypass portion (202) of the first part (20), through a puncture (2021) therein, and retracting the second sheath (3000) so as to deploy and implant a hook portion (301) of the second part (30) into the second 10 vessel (3), and deploy a bypass portion (302) of the second part (30) outside the second vessel (3), from the second vessel (3) to the first part (20), and within the lumen of the first part (20).

IPC Classes  ?

• A61F 2/07 - Stent-grafts
• A61F 2/06 - Blood vessels

Abstract

The present invention relates to a dry foam comprising agar-agar characterized by an elasticity modulus from 0.02 to 0.6 MPa, particularly from 0.15 to 0.6 MPa, more particularly from 0.3 to 0.4 MPa, a manufacturing process thereof and the uses thereof in particular as an embolization agent.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/12 - AerosolsFoams
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• A61L 24/08 - Polysaccharides
• A61L 31/04 - Macromolecular materials
• A61L 31/14 - Materials characterised by their function or physical properties
• A61L 31/16 - Biologically active materials, e.g. therapeutic substances
• A61L 31/18 - Materials at least partially X-ray or laser opaque
• C08J 9/12 - Working-up of macromolecular substances to porous or cellular articles or materialsAfter-treatment thereof using blowing gases generated by a previously added blowing agent by a physical blowing agent
• C08J 9/28 - Working-up of macromolecular substances to porous or cellular articles or materialsAfter-treatment thereof by elimination of a liquid phase from a macromolecular composition or article, e.g. drying of coagulum
• C08J 9/30 - Working-up of macromolecular substances to porous or cellular articles or materialsAfter-treatment thereof by mixing gases into liquid compositions or plastisols, e.g. frothing with air
• C08L 5/12 - Agar-agarDerivatives thereof

Abstract

The present invention relates to a dry foam comprising agar-agar characterized by an elasticity modulus from 0.02 to 0.6 MPa, particularly from 0.15 to 0.6 MPa, more particularly from 0.3 to 0.4 MPa, a manufacturing process thereof and the uses thereof in particular as an embolization agent.

IPC Classes  ?

• C08L 5/12 - Agar-agarDerivatives thereof
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• A61L 24/08 - Polysaccharides
• C08J 9/30 - Working-up of macromolecular substances to porous or cellular articles or materialsAfter-treatment thereof by mixing gases into liquid compositions or plastisols, e.g. frothing with air
• A61L 31/04 - Macromolecular materials
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/12 - AerosolsFoams
• C08J 9/12 - Working-up of macromolecular substances to porous or cellular articles or materialsAfter-treatment thereof using blowing gases generated by a previously added blowing agent by a physical blowing agent
• C08J 9/28 - Working-up of macromolecular substances to porous or cellular articles or materialsAfter-treatment thereof by elimination of a liquid phase from a macromolecular composition or article, e.g. drying of coagulum
• A61L 31/14 - Materials characterised by their function or physical properties
• A61L 31/16 - Biologically active materials, e.g. therapeutic substances
• A61L 31/18 - Materials at least partially X-ray or laser opaque

Abstract

A computer implemented method and a system of encryption of genomic data of a biological sample are provided, that improve the security of genetic information obtained from a sample, while guaranteeing traceability and identity-vigilance throughout the analysis chain. The computer implemented method and system disclosed herein allows a high level of identity-vigilance, improved labelling and traceability and provide a high level of confidentiality of genomics data.

IPC Classes  ?

• G16B 50/40 - Encryption of genetic data

Abstract

A computer implemented method and a system of encryption of genomic data of a biological sample are provided, that improve the security of genetic information obtained from a sample, while guaranteeing traceability and identity-vigilance throughout the analysis chain. The computer implemented method and system disclosed herein allows a high level of identity-vigilance, improved labelling and traceability and provide a high level of confidentiality of genomics data.

IPC Classes  ?

• G16B 50/40 - Encryption of genetic data

Abstract

Natural killer (NK) cells are innate cytotoxic lymphoid cells (ILCs) involved in the killing of infected and tumor cells. Several NK cell subsets have been reported in humans, but their heterogeneity between tissues remains to be fully characterized. The inventors previously showed, by single-cell RNA sequencing (scRNAseq) in human and mouse NK cells from spleen and blood, that the two major subsets, NK1 and NK2, are similar in different organs and species. They report here the identification, at single-cell resolution, of three subpopulations of NK cells in human bone marrow and an additional adaptive cell-like NK population in some cytomegalovirus-seropositive individuals. Pseudotime analysis identified a minor subset of resident CD56 bright NK cells, NK0 cells, as the precursor of both circulating CD56 dim NK1-like NK cells and CD56 bright NK2-like in the human bone marrow and spleen at steady state. Transcriptomic profiles of bone marrow NK cells from patients with acute myeloid leukemia (AML), a bone marrow disease, showed a stress-induced repression of NK cell effector functions relative to healthy NK cells, thus highlighting the profound impact of the disease on NK cell heterogeneity. Finally, the inventors investigated the potential role of CD160 in AML disease development and progression further, by studying the clinical outcome of cancer patients. Survival was much higher in patients with CD160-high AML than in those with CD160-low cancer, suggesting that CD160 is an anti-tumor biomarker in AML.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present invention relates to the field of medicine and in particular to the diagnostic and treatment of fibrosis. More particularly, the invention relates to CD146 and uses thereof as a biomarker in the diagnosis of fibrosis and as a therapeutic target in the treatment of fibrosis. The invention also relates to compositions and methods of detecting predisposition to, of diagnosing, prognosing and/or monitoring fibrosis in a subject. It further relates to CD146 inhibitors, and to compositions comprising a CD146 inhibitor, for use in prevention or treatment of fibrosis in a subject, as well as to compositions, kits and uses thereof in a diagnostic or therapeutic context.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 19/04 - Drugs for skeletal disorders for non-specific disorders of the connective tissue

Abstract

The invention relates to the field of imaging, diagnostic, internal vectorized radiotherapy and nuclear medicine. Inventors herein describe new products for use for labelling, detecting and/or imaging angiogenesis, vasculogenesis or a tissue or organ expressing the APJ receptor; for use for detecting, measuring, diagnosing, staging and/or monitoring angiogenesis, vasculogenesis, an angiogenesis- and/or vasculogenesis-related disease or disorder, and/or a disease or disorder inducing or modulating the expression of a APJ receptor in a tissue or organ; for use for preventing or treating angiogenesis, vasculogenesis, an angiogenesis- and/or vasculogenesis-related disease or disorder, and/or a disease or disorder inducing or modulating the expression of a APJ receptor in a tissue or organ; or for use for evaluating or monitoring the therapeutic effect of an angiogenic or antiangiogenic treatment or of an APJ receptor-targeted treatment. Compositions and kits comprising such products are also herein described as well as uses thereof.

IPC Classes  ?

• A61K 51/08 - Peptides, e.g. proteins

Abstract

CoronaviridaeCoronaviridae is a family of enveloped, positive-sense, single-stranded RNA viruses. The emergence of a new betacoronavirus SARS-CoV-2 has led to a major health-related crisis associated with a significant mortality in intensive care units, due to the pulmonary complications of COVID-19. The inventors showed that BAY-2402234 is suitable for inhibiting replication of coronavirus and thus would be suitable for the treatment of infections mediated by said type of virus.

IPC Classes  ?

• A61K 31/4196 - 1,2,4-Triazoles
• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
• A61K 31/4706 - 4-Aminoquinolines8-Aminoquinolines, e.g. chloroquine, primaquine
• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 31/14 - Antivirals for RNA viruses
• A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
• A61K 38/21 - Interferons

Abstract

CoronaviridaeCoronaviridae is a family of enveloped, positive-sense, single-stranded RNA viruses. The emergence of a new betacoronavirus SARS-CoV-2 has led to a major health-related crisis associated with a significant mortality in intensive care units, due to the pulmonary complications of COVID-19. The inventors showed that Vidofludimus is suitable for inhibiting replication of coronavirus and thus would be suitable for the treatment of infections mediated by said type of virus.

IPC Classes  ?

• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61P 31/20 - Antivirals for DNA viruses

Abstract

The present invention relates to an apheresis column loaded with a solid support comprising a composition comprising at least one peptide selected from the group consisting of: - the ?171-185cit peptide of amino acid sequence VDIDIKIX1SCX2GSCS (SEQ ID NO: 8) wherein X1 and X2 each represent a citrullyl residue, - the ?621-635Cit peptide of amino acid sequence X1GHAKSX2PVX3GIHTS (SEQ ID NO: 12) wherein X1, X2 and X3 each represent a citrullyl residue - the ?60-74Cit-??2 peptide of amino acid sequence X1PAPPPISGGGYX2AX3 (SEQ ID NO: 15) wherein X1 and X2 each represent a citrullyl residue and X3 represents a citrullyl derivative with a carboxamide group and - the peptide, referred to as the Ac-a36-50crt peptide, having the amino acid sequence GPX1VVEX2HQSACKDS (SEQ ID NO: 6) wherein the residue G at the N-terminal is acetylated and wherein X1 and X2 each represent a citrullyl residue and/or the ?36-50Cit peptide of amino acid sequence GPXIVVEX2HQSACKDS (SEQ ID NO: 5) wherein X1 and X2 each represent a citrullyl residue.

IPC Classes  ?

• A61K 38/36 - Blood coagulation or fibrinolysis factors
• C07K 1/22 - Affinity chromatography or related techniques based upon selective absorption processes
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• C07K 17/00 - Carrier-bound or immobilised peptidesPreparation thereof

Abstract

1212Cit123123Cit-ΝΗ21231231212CitI2122 each represent a citrullyl residue.

IPC Classes  ?

• A61M 1/36 - Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation

Abstract

A vascular prosthesis (1) configured to be implanted in a vessel, having substantially a T-shape, comprises a proximal tubular part (10) forming the base of the "T" and a distal tubular part forming the head of the "T". The proximal tubular part (10) has a first lumen, the distal tubular part has a second lumen, and the first and second lumens are fluidly connected to form a common lumen. The distal tubular part comprises a first end portion (210), a second end portion (220), and an intermediate portion (230) extending axially between the first and second end portions (210, 220). The first and second end portions (210, 220) are radially expandable. The proximal tubular part (10) is connected to the intermediate portion (230) and the second end portion (220) is movable between a retracted position in which the second end portion (220) is axially restrained and a deployed position in which the second end portion (220) is axially deployed.

IPC Classes  ?

• A61F 2/06 - Blood vessels
• A61F 2/856 - Single tubular stent with side portal passage
• A61F 2/915 - Stents in a form characterised by wire-like elementsStents in a form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
• A61F 2/82 - Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
• A61F 2/07 - Stent-grafts

Abstract

This magnetic emission device includes an antenna and further includes a device configured to select one of a plurality of predefined portions of the antenna and to connect the selected portion to a current-generating device in order both to cause the current to pass through the selected portion of the antenna so as to radiate a magnetic field, and to prevent the current from passing outside of the selected portion of the antenna.

IPC Classes  ?

• A61N 2/02 - Magnetotherapy using magnetic fields produced by coils, including single turn loops or electromagnets
• A61N 2/00 - Magnetotherapy

Abstract

Disclosed is a new vector for pharmacologically active water-insoluble molecules. These nanovectors, which are in the form of carbon nanoplatforms, are capable of solubilising the active molecules while reducing the side effects of the treatments. Also disclosed are the processes for synthesizing these nanoplatforms, as well as to the use thereof as a drug, particularly in the treatment of brain tumors.

IPC Classes  ?

• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61P 35/00 - Antineoplastic agents

Abstract

As advanced cancer has poor prognosis, its detection and treatment at the earliest stages is critical to increase cancer survival rate. Therefore, elucidating the determinants of the intra- lesion immune reaction during cancer's developments is critical for moving into precision medicine and immunotherapy-based cancer prevention. Adaptive immune response within tumors was shown to be the strongest at the earliest stage of carcinoma. Thus, the inventors hypothesized that the immune microenvironment and adaptive immunity were first established at early stage of lung carcinogenesis. Here they identified changes in the tumor molecular profile and its microenvironment during the successive steps of lung squamous carcinogenesis, using gene expression profiling and multispectral imaging. A unique and invaluable dataset of (9) morphological stages of development was analyzed, including (122) well-annotated biopsies from (77) patients. In particular, the inventors show that immune activation and immune escape occur before tumor invasion, and that immunosuppressive cytokines and checkpoint receptors immune escape mechanisms are concomitant with anti-tumor immunity in high-grade dysplasia. Thus, the present invention relates to methods of predicting and preventing cancer in subjects having premalignant lesions.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The present invention relates to field of treatment of rheumatoid arthritis. The inventors propose that PAD4, one of the enzymes which convert arginine into citrulline, is a target antigen for T cells that help the production of ACPA. They recently demonstrated that PAD immunization triggers anti-citrullinated fibrinogen antibody production in normal mice. Here, they demonstrate that the risk (OR) to develop RA associated with each of 12 HLA-DRB1 genotype correlates with the likelihood for the two HLA-DR molecules encoded by each genotype to bind at least one random peptide from PAD4, but not from citrullinated or native fibrinogen. PBLs from patients wih RA, PsA and controls proliferate to PAD4 and they identify, notably, a peptide from PAD4, p8 (SEQ ID NO: 6), that stimulates T cells from RA patients and a few patients with PsA. Proliferative responses to p8 are associated with RA, shared epitope positive HLA-DR alleles and antibodies to PAD4. Thus the present invention relates to a peptide derived from the PAD4 protein and its use in the treatment and prevention of rheumatoid arthritis.

IPC Classes  ?

• C12N 9/78 - Hydrolases (3.) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
• A61K 38/10 - Peptides having 12 to 20 amino acids
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

The present invention relates to the field of diagnostic and treatment of cancer, particularly melanoma, pancreatic cancer, kidney cancer and colon cancer. In particular, the invention relates to an antibody directed specifically to CD146-positive tumors and its applications, particularly for use as a medicament for the prevention and/or treatment of cancer, for use in a method of diagnostic or prognostic of a cancer, or for use as a radiotracer when labelled with a radioactive element.

IPC Classes  ?

• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• A61P 35/00 - Antineoplastic agents
• A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

Disclosed are mutated phosphotriesterase enzymes with improved stability and activity, as well as their use in particular for degrading organophosphorus compounds.

IPC Classes  ?

• C12N 9/16 - Hydrolases (3.) acting on ester bonds (3.1)
• A01N 63/50 - Isolated enzymesIsolated proteins
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

PLXDC2PLXDC2PLXDC2 rs927826 polymorphism explaining ~3.7% (p 7.5 10 -15PLXDC2PLXDC2PLXDC2 gene would be suitable for identifying a subject having or at risk of having a coagulation related disorder.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The present invention relates to a polyvalent culture medium for anaerobic bacteria under aerobic conditions in blood culture bottles. 2S), L-cysteine, ascorbic acid, glutathione, catalase, ubiquinol and lipoic acid.

IPC Classes  ?

• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12N 1/20 - BacteriaCulture media therefor

Abstract

The present invention relates to the field of medicine and in particular to the diagnostic and treatment of fibrosis. More particularly, the invention relates to CD146 and uses thereof as a biomarker in the diagnosis of fibrosis and as a therapeutic target in the treatment of fibrosis. The invention also relates to compositions and methods of detecting predisposition to, of diagnosing, prognosing and/or monitoring fibrosis in a subject. It further relates to CD146 inhibitors, and to compositions comprising a CD146 inhibitor, for use in prevention or treatment of fibrosis in a subject, as well as to compositions, kits and uses thereof in a diagnostic or therapeutic context.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The invention relates to a family of analogue compounds of squalamine for their use as a drug, in particular for treating or for preventing mycobacterial infections, in particular tuberculosis. A further aim of the present invention is new analogue compounds of squalamine and their use as a drug, in particular for treating or for preventing bacterial, fungal, viral, parasitic infections, or in the treatment of cancer in humans or animals, as well as pharmaceutical or veterinary compositions comprising said compounds. Finally, the invention relates to the use of these new compounds as disinfecting and/or decontaminating agents.

IPC Classes  ?

• A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• A61P 31/04 - Antibacterial agents
• A61P 31/10 - Antimycotics
• A61P 31/06 - Antibacterial agents for tuberculosis
• A61P 33/00 - Antiparasitic agents
• A61P 35/00 - Antineoplastic agents
• A61P 31/12 - Antivirals
• C07J 41/00 - Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
• C07J 1/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, not substituted in position 17 beta by a carbon atom, e.g. oestrane, androstane

Abstract

The invention is related to a method for measuring the variability of the red blood cells deformability of an individual by determining the amount of red blood cells having a tank-treading motion in a population of red blood cells from a tested blood sample of said individual, and comparing the amount to a reference amount. The determination of the amount of red blood cells having a tank-treading motion is carried out using a visualisation means such as a brightfield microscope.

IPC Classes  ?

• G01N 33/49 - Physical analysis of biological material of liquid biological material blood
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The disclosed magnetic emission device (100) comprises an antenna (102) and also means (106) which are designed to select one among a plurality of predefined portions of the antenna (102) and to connect the selected portion to a current-generating device (104) with a view to, on the one hand, causing the current to pass in the selected portion of the antenna (102) for radiation of a magnetic field and, on the other hand, preventing the current from passing outside the selected portion of the antenna (102).

IPC Classes  ?

• A61N 2/00 - Magnetotherapy
• A61N 2/02 - Magnetotherapy using magnetic fields produced by coils, including single turn loops or electromagnets

Abstract

The present invention concerns a method for determining a pathology of a human individual by analysis of a faecal material sample of said human individual by MALDI-TOF mass spectrometry, involving: a) determining a combination of a plurality of discriminating peaks for which thresholds of intensity values have been determined, making it possible to distinguish between the spectra of faecal material samples of individuals presenting said pathology and the spectra of faecal material samples of individuals not presenting said pathology, as a function of the values of the intensities of the so-called discriminating peaks; b) producing the spectrum of a faecal material sample to be analysed, and c) verifying whether the spectrum of said faecal material sample to be analysed includes said discriminating peaks and whether the values of the intensities of the discriminating peaks correspond to a combination of values of intensities corresponding to the spectra of individuals presenting said pathology or of individuals not presenting said pathology, as determined in step a).

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 30/72 - Mass spectrometers
• G01N 33/483 - Physical analysis of biological material

Abstract

in vitroinvitro PLIN1 PLIN1 PLIN1PLINIPLIN1 PLIN1 disease associated variant is indicative of a genetic predisposition to acute coronary syndrome in said subject.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The present invention relates to a new vector for pharmacologically active water-insoluble molecules. These nanovectors, which are in the form of carbon nanoplatforms, are capable of solubilising said active molecules while reducing the side effects of the treatments. The present invention also relates to the processes for synthesizing these nanoplatforms, as well as to the use thereof as a drug, particularly in the treatment of brain tumours.

IPC Classes  ?

• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 49/00 - Preparations for testing in vivo
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to methods for predicting the risk of developing a sepsis or a systemic inflammatory response syndrome (SIRS). Sepsis and SIRS are infectious complications representing major clinic issues. However, it is not possible to predict which patients will develop a SIRS and/or a sepsis and so to adjust the antibiotic or antifungal prophylaxis to the specific risk profile of each patient. Using high throughput transcriptomic and bioinformatics analysis, the inventors showed that eleven genes were differentially expressed and predicted the development of SIRS or sepsis at least 48 hours before its occurrence. In particular, the present invention relates to a method for predicting the risk of developing sepsis or/and systemic inflammatory response syndrome (SIRS) in a subject in need thereof, said method comprising determining the expression level of at least one gene among the eleven genes.

IPC Classes  ?

• C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The present invention relates to the field of diagnostic and treatment of cancer, particularly melanoma, pancreatic cancer, kidney cancer and colon cancer. In particular, the invention relates to an antibody directed specifically to CD146-positive tumors and its applications, particularly for use as a medicament for the prevention and/or treatment of cancer, for use in a method of diagnostic or prognostic of a cancer, or for use as a radiotracer when labelled with a radioactive element.

IPC Classes  ?

• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• A61K 51/10 - Antibodies or immunoglobulinsFragments thereof

Abstract

in vivoex vivoin vitroin vitro. More particularly, the invention relates to new soluble CD146 proteins usable in the context of human therapy, as well as to corresponding antibodies. The invention also relates to compositions comprising such compounds, particularly pharmaceutical or diagnostic compositions, including kits and the like, as well as methods of therapy or diagnosis using said compounds, compositions and cells.

IPC Classes  ?

• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants

Abstract

22S), L-cysteine, ascorbic acid, glutathione, catalase, ubiquinol and lipoic acid.

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor

Abstract

The invention relates to an aqueous extract used in particular for the regeneration of human or animal cells, in particular of mammals, comprising an aqueous extract free of any non-soluble solid debris of ground material of planarian organisms with a regeneration capacity, containing at least the intracellular components of the cells of said organisms of a cell lysate of said cells of said organisms.

IPC Classes  ?

• A61K 35/62 - LeechesWorms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
• A61K 8/99 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
• A61Q 19/08 - Anti-ageing preparations

Abstract

The invention relates to mutated phosphotriesterase enzymes that have improved stability and activity, as well as to the use of same particularly for degrading organophosphorus compounds.

IPC Classes  ?

• C12N 9/16 - Hydrolases (3.) acting on ester bonds (3.1)
• A61K 38/46 - Hydrolases (3)

Abstract

The present invention relates to a method of predicting or monitoring the sensitivity of a subject having a cancer, in particular renal cell carcinoma (RCC) to sunitinib, to a method of selecting an appropriate treatment of cancer, to a method of screening or identifying a compound suitable for improving the treatment of a cancer, and to corresponding kits.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present invention relates to a method for preparing a two-phase culture medium (1) packaged in a tube (2) intended for culturing bacteria aerobically, comprising the following consecutive steps: a.1) pouring into the bottom of the tube a first aqueous medium capable of being frozen or gelled, and tilting said tube according to a predetermined inclination with respect to the vertical; and a.2) freezing or gelling said first medium until forming a first solid layer so that the upper surface of the first layer has a predetermined inclination (α2) with respect to the axis (XX') of said tube; and b.1) pouring into the tube a second aqueous medium which is a culture medium capable of forming a solid culture medium, and tilting said tube according to a predetermined inclination (α1) of the longitudinal axis (XX') thereof with respect to the vertical so as to form a second layer of said second medium above said first layer; and b.2) gelling said medium until forming a second layer of said gelled solid culture medium.

IPC Classes  ?

• C12N 1/04 - Preserving or maintaining viable microorganisms
• C12N 1/20 - BacteriaCulture media therefor
• C12M 1/24 - Apparatus for enzymology or microbiology tube or bottle type

Abstract

The present invention relates to a method for preserving a sample of a set of aerobic and anaerobic bacteria other than lactic acid bacteria, in particular intestinal microbiota bacteria, preferably a human stool sample, and a lyophilisate obtained using the method, said method comprising the following successive steps, wherein: a) a said sample of a set of said bacteria is prepared by means of dilution in an aqueous storage medium comprising a combination of protective agents comprising (a1) at least one antioxidant compound and (a2) at least one sugar, and preferably (a3) milk proteins, and b) freezing said sample recovered in step b) in liquid nitrogen at approximately -196°C for no more than one minute, preferably for 30 to 50 seconds, and c) carrying out lyophilisation on said frozen sample to obtain a lyophilisate.

IPC Classes  ?

• C12N 1/04 - Preserving or maintaining viable microorganisms

Abstract

The present invention relates to a specific culture medium for the culture and selective isolation of an Enterococcus hirae bacterium, consisting of nutrients other than sugars of a basic culture medium for the culture of enterococci devoid of esculin, comprising inhibitors of Gram-negative bacteria and of Gram-positive bacteria other than enterococci, and preferably at least one antifungal compound, characterized in that it comprises: - as inhibitor of Gram-positive bacteria other than enterococci, sodium chloride at a concentration of at least 20 g/l and no more than 60 g/l; - mannitol as the sole sugar; and - as sole dye, a coloured indicator that changes colour at a pH less than the pH of said specific culture medium, corresponding to the acidification of the specific culture medium resulting from the consumption of the mannitol.

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor

Abstract

The present invention relates to a method for in vitro culture of a line of eukaryotic cells of a multicellular organism, characterised in that uric acid is added to the cell culture medium and the culture is carried out in an aerobic atmosphere not supplemented with CO2, the multiplication of said cells being capable of being improved by culture in an atmosphere supplemented with CO2, in the absence of uric acid in said culture medium. In particular, an intracellular culture of microorganisms is produced in said cells in a cell culture medium.

IPC Classes  ?

• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor

Abstract

The present invention relates to the treatment and the diagnosis of the hereditary xerocytosis (HX). The inventors showed that in case of HX due to mutations in PIEZO1, KCNN4 activation is responsible for erythrocyte dehydration, and that said dehydration is reversed by the inhibition of the Gardos channel (KCNN4 protein). Thus the invention relates to an inhibitor of the Gardos channel for use in the treatment of HX in a subject which is the carrier of at least one mutation of the PIEZO1 gene. Particularly, the inventors demonstrated that Senicapoc is efficient to prevent dehydration of patient erythrocytes with PIEZO mutation. They also identified that mutations V598M or F681S of the PIEZO1 channel lead to a gain of function of the channel and participate in HX physiopathology. Thus the present invention also relates to an in vitro method of diagnosing HX, comprising the detection in a biological sample of the presence of any one of these mutations.

IPC Classes  ?

• A61K 31/15 - Oximes (C=N—O—)Hydrazines (N—N)Hydrazones (N—N=)
• A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
• A61K 31/16 - Amides, e.g. hydroxamic acids
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
• A61K 31/4164 - 1,3-Diazoles
• A61K 31/4174 - Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
• A61K 31/421 - 1,3-Oxazoles, e.g. pemoline, trimethadione
• A61K 31/4245 - Oxadiazoles
• A61K 31/4422 - 1,4-Dihydropyridines, e.g. nifedipine, nicardipine
• A61K 31/661 - Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid

Abstract

The invention relates to imaging, diagnostic, prognostic and therapy in the general field of nuclear medicine. Inventors herein describe new products for use for labelling, detecting, imaging, measuring, diagnosing, staging and/or monitoring angiogenesis and/or vasculogenesis, for preventing angiogenesis and/or vasculogenesis, or for preventing or treating an angiogenesis- and/or vasculogenesis-related disease or disorder. Compositions and kits comprising such products are also herein described as well as uses thereof.

IPC Classes  ?

• A61K 51/08 - Peptides, e.g. proteins
• A61P 35/00 - Antineoplastic agents
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61K 103/00 - Radioactive metals
• A61K 101/02 - Halogens
• A61K 103/20 - Indium
• A61K 103/32 - Yttrium
• A61K 103/40 - Actinides
• A61K 103/30 - Rare earths

Abstract

The invention concerns a device (DV1) comprising means (20, 21, 22, P1, M1, PAP) for acquiring a piece of physiological data (PD), from a physiological signal (SP), and means (10, 11, 12, P1, M1) for acquiring a piece of biometric data (BD), the device being configured to perform the acquisition (S02) of the biometric data (BD) and the acquisition (S01) of the physiological data (PD) simultaneously, and, in response to a request to transfer the physiological data, to transfer the physiological data accompanied by the biometric data or a piece of data depending on the biometric data, or to transfer it in an encoded form depending on the biometric data, or indeed to only transfer it upon prior presentation of the biometric data or a piece of data depending on the biometric data.

IPC Classes  ?

• A61B 5/1172 - Identification of persons based on the shapes or appearances of their bodies or parts thereof using fingerprinting
• A61B 5/0404 - Hand-held devices
• A61B 5/024 - Measuring pulse rate or heart rate
• G06F 19/00 - Digital computing or data processing equipment or methods, specially adapted for specific applications (specially adapted for specific functions G06F 17/00;data processing systems or methods specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes G06Q;healthcare informatics G16H)
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• G06F 21/62 - Protecting access to data via a platform, e.g. using keys or access control rules

Abstract

The present invention relates to a selective multipurpose culture medium for isolating and selecting, from samples containing them, bacteria chosen from (a) colistin-resistant fermentative and nonfermentative Gram-negative bacteria and (b) vancomycin-resistant Gram-positive bacteria, characterized in that it essentially consists of an agar with a chromogenic agent added thereto, consisting of bromocresol purple, a sugar and two antibiotic compounds consisting of vancomycin and colistin. The present invention also relates to a method for isolating and selecting said colistin-resistant Gram-negative bacteria and vancomycin-resistant Gram-positive bacteria by culturing a sample of bacteria containing same, using a solid culture medium according to the invention.

IPC Classes  ?

• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor

Abstract

The present invention relates to a transport and/or storage medium containing or intended to contain a sample of mycobacteria of the Mycobacterium tuberculosis complex for transporting and/or storing said mycobacteria of the Mycobacterium tuberculosis complex, comprising a culture medium made up of said mycobacteria and antibiotics that are not active against the microbacteria and at least one decontaminating agent, characterised in that it also comprises complete supernatant for the culture of the BCG strain of Mycobacterium bovis as an additional component.

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
• C12N 1/38 - Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factorsStimulation of growth by removal of a chemical compound
• C12R 1/32 - Mycobacterium

Abstract

The present invention relates to the field of human fertility treatment. The present invention more specifically relates to the identification of soluble CD146 (sCD146) as a biomarker which, when measured in an embryo culture medium, can be used to determine whether the embryo can be selected for implantation in the uterus of a mammal or not. The present invention thus provides a new tool and related kits to (pre)select embryo eligible for implantation. The invention also relates to methods for promoting pregnancy in a human who undergoes embryo transfer.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• A61B 17/435 - Gynaecological or obstetrical instruments or methods for reproduction or fertilisation for embryo transplantation

Abstract

The present invention relates to a combination of a first antibiotic compound, Colistin, and a second antibiotic compound, selected from among Sulfadiazine and fusidic acid, for use in therapeutic treatment against pathogenic enterobacteria which are not naturally intrinsically resistant, but which have acquired resistance to at least Colistin.

IPC Classes  ?

• A61K 38/12 - Cyclic peptides
• A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
• A61P 31/04 - Antibacterial agents
• A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol

Abstract

A blood flow reducer (20) for insertion in a blood vessel, the reducer (20) being adapted to be deformed from a first configuration to an expanded configuration, wherein, in the expanded configuration, the reducer (20) defines an axial lumen (40) for allowing blood flow therethrough, the axial lumen (40) having a smallest cross-section, the reducer (20) has a largest cross-section, and the smallest cross-section is comprised between 20% and 90% of the largest cross-section. In particular, the smallest cross-section is strictly comprised between 70% and 90% of the largest cross-section. A method for preconditioning a liver of a living being before partial hepatectomy, wherein a 10 to 30% stenosis is created in a branch of a portal vein conducting blood to a first liver lobe.

IPC Classes  ?

• A61B 17/12 - Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord

Abstract

The invention concerns a method for detecting at least one cardiac rhythm disturbance of a human or animal subject from a time series of intervals RR representative of the cardiac rhythm of the subject, extracted from a physiological signal (S). The method comprises a step (S07) of characterising the time series with at least one descriptive variable (Vb), the value of which is calculated from a derivative series (Sj2, Sj3, Sj4, Sj5, Sj6, Sj7) of which the constituent element is a discrete derivative of the order of 1 or greater than 1 of the interval RR of the time series.

IPC Classes  ?

• A61B 5/046 - Detecting fibrillation
• A61B 5/024 - Measuring pulse rate or heart rate

Abstract

The invention relates to a device (DV3) for detecting a cardiac rhythm disturbance in a subject, comprising a channel (CH1) for acquiring a photoplethysmographic signal (S1) and at least one channel (CH2) for acquiring an electrocardiographic signal (S2). A processor (P3) is configured to detect a disturbance in the cardiac rhythm in the photoplethysmographic signal (S1) and in the electrocardiographic signal (S2).

IPC Classes  ?

• A61B 5/0452 - Detecting specific parameters of the electrocardiograph cycle
• A61B 5/024 - Measuring pulse rate or heart rate

Abstract

The present invention relates to a method of interpreting different antibiogram images in which it is possible to recognize a phenotype of bacterial resistance relative to antibiotics by comparing photographs using a photographic image bank of the reference antibiogram without any need to interpret them using the EUCAST or CA-SFM interpretation data; providing that for a given phenotype, there is available a collection of photographs of a plurality of bacteria of the same species and of the same phenotype.

IPC Classes  ?

• C12Q 1/20 - Testing for antimicrobial activity of a material using multifield media
• G06T 7/00 - Image analysis
• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
• C12Q 1/18 - Testing for antimicrobial activity of a material

Abstract

The present invention relates to methods for predicting the survival time of subjects suffering from melanoma metastases. In particular, the present invention relates to a method for predicting the survival time of a subject suffering from melanoma metastases comprising i) determining the expression level of HVEM in a metastasis tissue sample ii) comparing the expression level determined at step i) with a predetermined reference value and iii) concluding that the subject will have a short survival time when the expression level determined at step i) is higher than the predetermined reference value or concluding that the subject will have a long survival time when the expression level determined at step i) is lower than the predetermined reference value.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum

Abstract

The invention relates to an in vitro method of diagnosis of hereditary xerocytosis in a subject, comprising genotyping the KCNN4 gene encoding the Gardos channel in said subject. The invention also relates to an inhibitor of the KCNN4 protein for use in the treatment of hereditary xerocytosis, in particular in a human subject who is a carrier of the missense mutation c.1055G>A or c.844G>A in the KCNN4 gene.

IPC Classes  ?

• A61K 31/00 - Medicinal preparations containing organic active ingredients
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid

Abstract

The present invention relates to the field of human fertility treatment. The present invention more specifically relates to the identification of soluble CD 146 (sCD146) as a biomarker which, when measured in an embryo culture medium, can be used to determine whether the embryo can be selected for implantation in the uterus of a mammal or not. The present invention thus provides a new tool and related kits to (pre)select embryo eligible for implantation. The invention also relates to methods for promoting pregnancy in a human who undergoes embryo transfer.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention relates to the field of human fertility treatment. The present invention more specifically relates to the identification of soluble CD 146 (sCD146) as a biomarker which, when measured in an embryo culture medium, can be used to determine whether the embryo can be selected for implantation in the uterus of a mammal or not. The present invention thus provides a new tool and related kits to (pre)select embryo eligible for implantation. The invention also relates to methods for promoting pregnancy in a human who undergoes embryo transfer.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

A blood flow reducer (20) for insertion in a blood vessel, the reducer (20) being adapted to be deformed from a first configuration to an expanded configuration, wherein, in the expanded configuration, the reducer (20) defines an axial lumen (40) for allowing blood flow therethrough, the axial lumen (40) having a smallest cross-section, the reducer (20) has a largest cross-section, and the smallest cross-section is comprised between 20% and 90% of the largest cross-section. In particular, the smallest cross-section is strictly comprised between 70% and 90% of the largest cross-section. A method for preconditioning a liver of a living being before partial hepatectomy, wherein a 10 to 30% stenosis is created in a branch of a portal vein conducting blood to a first liver lobe.

IPC Classes  ?

• A61B 17/12 - Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord

Abstract

The invention relates to a proteasome inhibitor for use for treating and/or preventing a disorder related to an accumulation of a non-degraded abnormal protein, particularly a premature ageing disorder. The invention also relates to the use of proteasome inhibitors for attenuating physiological ageing. The invention also relates to the use of proteasome inhibitors in the treatment and/or prevention of age-related disorders and their metabolic consequences. The invention also relates to the dermato logical, dermo cosmetic or cosmetic use of a proteasome inhibitor for preventing and/or attenuating skin ageing. The invention also relates to the use of proteasome inhibitors in the treatment of cancer.

IPC Classes  ?

• A61K 38/06 - Tripeptides
• A61K 8/64 - ProteinsPeptidesDerivatives or degradation products thereof
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The invention relates to a monoclonal antibody that recognises bacteria Borrelia crocidurae, directed against the flagellin protein or the VLP protein of bacteria Borrelia crocidurae, as well as to a method for the in vitro or ex vivo detection of bacteria Borrelia crocidurae or Borrelia duttonii in a biological sample.

IPC Classes  ?

• C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 33/577 - ImmunoassayBiospecific binding assayMaterials therefor involving monoclonal antibodies

Abstract

The invention relates to a method of diagnosis or prognosis of an obliterative arteriopathy in a subject, comprising determining the expression level of adenosine A2A receptors expressed at the cell surface of peripheral blood mononuclear cells obtained from said subject. The invention also relates to an agonist-like monoclonal antibody directed to the human adenosine A2A receptor, useful for carrying out this method.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• G01N 33/74 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving hormones

Abstract

The present invention relates to a method for identifying a microbe in a clinical sample by comparing mass spectra obtained by MALDI-TOF mass spectrometry of a sample of a protein extract of said sample to be analysed containing one such microbe, by comparison with reference spectra, characterised in that it comprises the following steps: a) establishing a bank of reference spectra by MALDI-TOF mass spectrometry, performed on samples of protein extracts obtained according to the same protocol from clinical samples after microbial lysis, without isolating and/or without culturing said microbes; b) obtaining a spectrum of a sample to be analysed of protein extract obtained from a clinical sample of the same nature obtained according to the same protocol; and c) determining that said clinical sample from which a sample to be analysed has been obtained contains a given reference microbe selected among the various reference microbes of said reference bench if the spectrum of step b) to be analysed is found to contain all the spikes that characterise such a reference spectrum of a reference sample containing said given reference microorganism.

IPC Classes  ?

• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/493 - Physical analysis of biological material of liquid biological material urine
• H01J 49/00 - Particle spectrometers or separator tubes

Abstract

The present invention relates to a method for interpreting different images of antimicrobial susceptibility tests. According to said method, an antibiotic resistance phenotype may be recognized by comparing photos using a photographic image bank of the reference antimicrobial susceptibility test from without needing to interpret said images according to EUCAST or CA-SFM interpretation data; provided that for a given phenotype, access to a collection of photos of several bacteria of the same species and the same phenotype is available.

IPC Classes  ?

• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
• C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters
• C12Q 1/18 - Testing for antimicrobial activity of a material
• G01N 21/00 - Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
• G06T 7/00 - Image analysis

Abstract

The invention relates to a liquid medium and to a method allowing the transport and the preservation of samples containing anaerobic and/or aerobic bacteria in ambient air, that can preserve the viability of said bacteria with a view to the subsequent culturing and isolation thereof.

IPC Classes  ?

• C12N 1/04 - Preserving or maintaining viable microorganisms
• C12R 1/145 - Clostridium
• C12M 1/28 - Inoculator or sampler being part of container

Abstract

The present invention relates to a method for monitoring the outcome of a given cancer in a blood sample of a patient. It also relates to a method for diagnosing a given cancer in a blood sample of a patient, comprising the following steps: a) measuring the concentrations of platelet microparticles, erythrocyte microparticles, leukocyte microparticles and fibrin positive microparticles, in said sample, b) comparing the respective concentrations obtained in step a) to the respective ranges of reference values, and c) if all the concentrations obtained in step a) are included in said respective ranges of reference values, establishing that said patient suffers from a given cancer.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present disclosure relates to a compound which inhibits the binding of SLIT2 to ROBO or ROB02 or a compound which is an inhibitor of SLIT2, ROBO1 or ROB02 gene expression for use as an inhibitor of the neuronal remodeling in cancer.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

A method of identifying in vitro molecular causes of Charcot Marie Tooth disease, comprising the following steps: (i) providing a physiological sample comprising a genome of a subject, and (ii) implementing on said sample at least one of Process A and Process B, wherein - Process A is determining a number of copy number variation(s), with respect to a sample of a normal subject, on all the 23 genes of Group 1 in Table 1 and at least 20 genes selected from the 30 genes of Group 2 in Table 1; and - Process B is determining a number of point mutation(s), with respect to a sample of a normal subject, on all the 23 genes of Group 1 in Table 1 and at least 20 genes selected from the 30 genes of Group 2 in Table 1.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The present invention relates to a method for detecting microbial contamination of a blood product sample to be analysed, including the following steps: a) performing a lysis treatment of at least said microbe which can be contained in said sample to be analysed after an incubation time t, b) producing a mass-spectrometry spectrum, preferably a MALDI-TOF spectrum, of said sample or of a protein extract of said sample thus lysed at a time t, and c) determining whether said sample to be analysed is contaminated by comparing the obtained spectrum with at least one MALDI-TOF mass spectroscopy spectrum selected among the following spectra: c1) at least one reference spectrum selected among: c.1.1 - at least one spectrum of one so-called standard sample of the same type as said sample to be analysed, but not contaminated, and c.1.2 - spectra of said standard samples of the same type, each contaminated respectively with a different known microbe, and c.2) at least one spectrum of a so-called original sample prior to incubation or after an incubation time t' other than t.

IPC Classes  ?

• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention relates to a method for analysing a biological sample to be analysed, in which the following successive steps are carried out: a) a mass spectrum, preferably a MALDI-TOF mass spectrum, of said sample to be analysed, called spectrum to be analysed, is produced, b) at least one MALDI-TOF mass spectrum of a reference sample, called reference spectrum, is produced, and c) said spectrum to be analysed is compared with a said reference spectrum essentially by calculating the subtraction between the respective total areas of the spectrum to be analysed and of the reference spectrum.

IPC Classes  ?

• G06F 19/24 - for machine learning, data mining or biostatistics, e.g. pattern finding, knowledge discovery, rule extraction, correlation, clustering or classification
• G06K 9/00 - Methods or arrangements for reading or recognising printed or written characters or for recognising patterns, e.g. fingerprints
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor

Abstract

The invention relates to i) a ligand of HVEM, and ii) an immunotoxin, as a combined preparation for simultaneous, separate or sequential use in the treatment of a solid tumor.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof

Abstract

The present invention relates to antibodies conjugated to at least one nucleic acid molecule and their use in multiplex immuno-detection assays. In particular, the present invention relates to an antibody conjugated to at least one nucleic acid molecule comprising an enzymatic cleavable sequence (CL) and a DNA barcode sequence N1N2N3N4Nn wherein N represents a nucleotide and n an integer number superior to 4.

IPC Classes  ?

• G01N 33/532 - Production of labelled immunochemicals
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances

Abstract

The invention relates to a method for detecting the presence of antinuclear autoantibodies (ANA) in a biological sample of a subject, typically of a human being, and, when present, determining the titer of the tested sample. Such a method can be used in particular to diagnose a disease and to monitor the efficiency of a treatment of said disease in a subject.

IPC Classes  ?

• G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
• G06T 7/00 - Image analysis

Abstract

The anatomically accurate mannequin for simulating behaviours of a human body comprises a neck (18), a mouth cavity (20) and a larynx (24). The larynx (24) extends the mouth cavity (20) and is mounted such that it can move in the neck (18) between a position, referred to as the down position, in which the larynx (24) is at rest, and a deglutition position referred to as the up position.

IPC Classes  ?

• G09B 23/28 - Models for scientific, medical, or mathematical purposes, e.g. full-sized device for demonstration purposes for medicine
• G09B 23/32 - Anatomical models with moving parts

Abstract

The present invention relates to methods and pharmaceutical compositions for the treatment of X-linked Charcot-Marie-Tooth. In particular, the present invention relates to a method for the treatment of CMTX in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an inhibitor of CamKII activity or expression.

IPC Classes  ?

• A61K 31/18 - Sulfonamides
• C07C 311/29 - Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
• C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 403/02 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings

Abstract

The present invention includes methods and kits for detecting, diagnosing, for obtaining a prognosis, staging and monitoring an inflammatory condition in a subject involving detecting, identifying or assaying for soluble B7-H6polypeptides. It may also be used for evaluating the efficacy of treatment of an inflammatory condition.

IPC Classes  ?

• G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention provides a method for determining all the molecular causes of Inherited Neuromuscular Disorders comprising determining a number of copy number variation(s), and/or determining a number of point mutation(s) on a physiological sample comprising a genome of a subject.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The present invention relates to antigen binding formats for use in therapeutic treatments or diagnostic assays. The present invention relates to an antigen-binding format consisting of: —a first fusion protein wherein the CH1 constant domain of an antibody is fused i) by its N-terminal end to the C-terminal end of a variable domain of an antibody and ii) by its C-terminal end to the N-terminal end of a variable domain of an antibody and, —a second fusion protein wherein the CL constant domain of an antibody is fused by its N-terminal end to the C-terminal end of a variable domain of an antibody.

IPC Classes  ?

• C07K 16/46 - Hybrid immunoglobulins
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells

Abstract

The present invention relates to an in vitro method for diagnosing scleroderma in a subject, said method comprising the step of detecting in a biological sample obtained from the subject one or more autoantibodies recognizing one or more protein biomarkers selected from the group of proteins consisting of THEXl, AIFl, FGF2, EphB2, CLK1 and ANKS6.

IPC Classes  ?

• G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention relates to the use of matrix metalloproteinase- 2 (MMP2) as a predictive biomarker of response to antiangiogenic therapy and survival after antiangiogenic therapy in cancer patients, and to related methods for predicting or monitoring the response to an antiangiogenic treatment and the survival after said treatment of a cancer patient.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present invention relates to a method for determining the tumoral or non-tumoral nature, or the tumor and/or cancer type, of a solid human or animal organ fragment of a given person or animal by analyzing the MALDI-TOF mass spectrometry spectrum or spectra. Said method is characterized in that the following consecutive steps are carried out, consisting of: 1) preparing a first sample of a uniform suspension of the homogenate of said fragment, said suspension containing a mixture of different types of unlysed whole cells; 2) creating at least one spectrum of at least one so-called first sample, and analyzing said spectrum by means of comparison with at least one reference profile, said reference profile being made up of at least one list of reference peak(s) for a spectrum or spectra set up on reference fragments known to be tumoral or non-tumoral, or if tumoral, known to belong to a so-called tumor or cancer class or sub-class; and 3) determining whether or not said tissue fragment from said first sample is tumoral or non-tumoral, or belongs to a so-called tumor or cancer class or sub-class, according to the presence or absence of said reference peaks and/or according to the value of the area of said reference peak(s) in the spectrum of said sample.

IPC Classes  ?

• G01N 27/62 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosolsInvestigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electric discharges, e.g. emission of cathode
• G01N 30/72 - Mass spectrometers
• G01N 33/483 - Physical analysis of biological material
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present invention relates to the use of a compound chosen from squalamine and a squalamine-analogue aminosteroid compound, as an agent for disinfecting an inert-material object, in particular the predisinfection of a medical, dental, diagnostic or surgical material. The present invention also provides an aqueous or water-soluble disinfecting composition which is beneficial for a use according to the invention, characterized in that it comprises, as disinfecting active compound, a said compound chosen from squalamine and a said squalamine-analogue aminosteroid compound which is antibacterial and antifungal, with excipients that are appropriate for a water-soluble or aqueous formulation.

IPC Classes  ?

• A01P 1/00 - DisinfectantsAntimicrobial compounds or mixtures thereof
• A01P 3/00 - Fungicides
• A01N 49/00 - Biocides, pest repellants or attractants, or plant growth regulators containing compounds containing the group wherein m+n≥1, both X together may also mean —Y— or a direct carbon-to-carbon bond, and the carbon atoms marked with an asterisk are not part of any ring system other than that which may be formed by the atoms X, the carbon atoms in square brackets being part of any acyclic or cyclic structure, or the group wherein A means a carbon atom or Y, n ≥ 0, and not more than one of these carbon atoms being a member of the same ring system, e.g. juvenile insect hormones or mimics thereof
• A01N 63/02 - Substances produced by, or obtained from, microorganisms or animals
• A61L 2/18 - Liquid substances

Abstract

The present invention relates to a method for monitoring the tumor growth of an androgen-independent prostate cancer in a subject, by determining the amount of at least one adrenomedullin receptor and optionally adrenomedullin in a prostate cancer cell obtained from said subject. The present invention also relates to a pharmaceutical composition comprising an anti-adrenomedullin antagonist antibody and/or at least one anti-adrenomedullin receptor antagonist antibody for treating an androgen-independent prostate cancer.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to the culturing and detection of a novel methanogenic archaeon designated as Methanomassiliicoccus luminyensis, which has been isolated and cultured from human stool samples, including the 16S rDNA gene sequence of SEQ. ID. No. 1, as has been filed under no. DSM 24529 in the DSMZ collection (Germany), as well as to a method for culturing and detecting said archaeon by means of enzymatic amplification by PCR.

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12R 1/01 - Bacteria or actinomycetales

Abstract

The invention relates to in vitro methods for the detection of an autoimmune disease or of a high-risk pregnancy in a subject, or for the determination of the predisposition of a subject to develop an autoimmune disease, to develop a high-risk pregnancy or to experience an implantation failure, comprising the determination of the presence of and/or the measure of the quantity of anti-CD 146 auto-antibodies in a biological sample of the subject and comparison to a control value.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The invention relates to a method of determining whether a subject has or is at risk of developing a dementia, such as Alzheimer's disease (AD), a mild cognitive impairment (MCI), fronto-temporal dementia (FTD), or dementia with Lewis bodies (DLB), which method comprises detecting the presence of a mutation, deletion or insertion of one or several nucleotides in the CTGF gene locus in a biological sample of said subject.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids